NASDAQ:APVO Aptevo Therapeutics (APVO) Stock Price, News & Analysis $1.86 +0.03 (+1.64%) As of 10:48 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About Aptevo Therapeutics Stock (NASDAQ:APVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aptevo Therapeutics alerts:Sign Up Key Stats Today's Range$1.82▼$1.8850-Day Range$1.71▼$4.7652-Week Range$1.37▼$35.64Volume6,978 shsAverage Volume107,504 shsMarket Capitalization$3.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Aptevo Therapeutics Inc. (NASDAQ:APVO) is a biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s research programs are designed to engage the immune system and direct it against specific disease-related cells or targets. Aptevo’s pipeline is based primarily on its ADAPTIR and ADAPTIR-FLEX platform technologies, which support the development of engineered, multispecific antibodies. These programs have included investigational candidates such as APVO436, an immune-cell engager being studied in hematologic malignancies, and other compounds aimed at treating solid tumors and blood cancers. The company’s candidates remain subject to clinical and regulatory development. Aptevo was established in 2016 through a spin-off from Emergent BioSolutions, receiving certain antibody-based technologies and commercial products as part of the transaction. The company is headquartered in Seattle, Washington, and conducts its development activities through collaborations, clinical research, and regulatory programs intended to serve patients in major global healthcare markets.AI Generated. May Contain Errors. Read More Aptevo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreAPVO MarketRank™: Aptevo Therapeutics scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingAptevo Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAptevo Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Aptevo Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aptevo Therapeutics are expected to grow in the coming year, from ($19.30) to ($6.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptevo Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptevo Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAptevo Therapeutics has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aptevo Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.42% of the float of Aptevo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAptevo Therapeutics has a short interest ratio ("days to cover") of 0.56, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptevo Therapeutics has recently increased by 59.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAptevo Therapeutics does not currently pay a dividend.Dividend GrowthAptevo Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.39 News SentimentAptevo Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aptevo Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.37% of the stock of Aptevo Therapeutics is held by insiders.Percentage Held by Institutions8.06% of the stock of Aptevo Therapeutics is held by institutions.Read more about Aptevo Therapeutics' insider trading history. Receive APVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APVO Stock News HeadlinesAptevo Therapeutics (NASDAQ:APVO) Share Price Passes Below 50 Day Moving Average - Should You Sell?September 18, 2026 | americanbankingnews.comAptevo Reports 93% Clinical Benefit With Mipletamig Triplet In TP53-Mutated AML; Stock Down 17%September 3, 2026 | rttnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.September 25 at 1:00 AM | Banyan Hill Publishing (Ad)Aptevo reports 93% clinical benefit rate for Mipletamig triplet in TP53-mutated AMLSeptember 3, 2026 | msn.comAPVO: Focusing on Three Key Areas of DevelopmentAugust 24, 2026 | finance.yahoo.comAptevo Shareholders Back Board, Auditor and Incentive PlanAugust 21, 2026 | tipranks.comAptevo APVO Reports Q2 2026 Update With $9.8 Million CashAugust 14, 2026 | quiverquant.comQAPVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune EngagementJune 16, 2026 | finance.yahoo.comSee More Headlines APVO Stock Analysis - Frequently Asked Questions How have APVO shares performed this year? Aptevo Therapeutics' stock was trading at $9.43 at the start of the year. Since then, APVO shares have decreased by 80.6% and is now trading at $1.83. How were Aptevo Therapeutics' earnings last quarter? Aptevo Therapeutics Inc. (NASDAQ:APVO) released its quarterly earnings data on Friday, August, 14th. The biotechnology company reported ($5.31) earnings per share for the quarter, beating the consensus estimate of ($6.02) by $0.71. When did Aptevo Therapeutics' stock split? Aptevo Therapeutics's stock reverse split on Wednesday, March 6th 2024.The 1-44 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, March 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Aptevo Therapeutics? Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aptevo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptevo Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA), Plug Power (PLUG) and Micron Technology (MU). Company Calendar Last Earnings8/14/2026Today9/25/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (63m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 APVO's financial health is in the Red zone, according to TradeSmith. APVO has been in this zone for over 63 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:APVO CIK1671584 Webwww.aptevotherapeutics.com Phone(206) 838-0500Fax206-838-0503Employees33Year Founded2016Profitability EPS (Trailing Twelve Months)($51.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-201.49% Return on Assets-119.21% Debt Debt-to-Equity RatioN/A Current Ratio2.08 Quick Ratio2.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$17.42 per share Price / Book0.11Miscellaneous Outstanding Shares1,810,000Free Float1,803,000Market Cap$3.36 million OptionableNot Optionable Beta1.60 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:APVO) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
